Site Logo

Hello, you are using an old browser that's unsafe and no longer supported. Please consider updating your browser to a newer version, or downloading a modern browser.

Safety Surveillance During Drug Development: Comparative Evaluation of Existing Regulations

Thursday, April 13, 2023

UBC is proud to announce the publication of members of our pharmacovigilance team in Advances in Therapy. The article – “Safety Surveillance During Drug Development: Comparative Evaluation of Existing Regulations” – features contributions from Safety Scientists Christopher Henry, Alix Garcia, Chysanthi Samara, Safety Physician Laure Valotton, and Pharmacovigilance Physician Leader Alexis Pincon.

Safety surveillance during drug development is a globally recognized necessity. However, different regions and countries have different standards for what is required, leading to safety processes that need to be harmonized. This research analyzes the current regulations and seeks out solutions to increase the global viability of safety surveillance during drug development.

To read the full paper, click here.

UBC’s pharmacovigilance team excels at handling every aspect of your safety requirements at all stages of the drug lifecycle. Our commitment to Patients First has driven us to balance high-tech solutions with a personalized, experienced touch in our services. To learn more about UBC’s physician-driven pharmacovigilance offering, click here. To contact our team directly, click here.